Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Influenza virus vaccine

A type of influenza virus and vaccine technology, applied in the direction of virus antigen components, antibody medical components, fermentation, etc., can solve the problem of not being able to extend type B influenza virus

Inactive Publication Date: 2006-04-05
MERCK & CO INC +1
View PDF8 Cites 14 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0011] However, this approach cannot be extended to influenza B viruses because there is no vaccine target equivalent to M2.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Influenza virus vaccine
  • Influenza virus vaccine
  • Influenza virus vaccine

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0148] Preparation of peptides

[0149] A synthetic peptide representing a portion of the M2 protein sequence and containing a C-terminal or N-terminal reactive bromoacetyl or maleimide group is prepared by a solid-phase chemical synthesis method commonly used in the art.

[0150] For example, C-terminal bromoacetylated M215-mer, CT-BrAcM2-15mer, Ac-Ser-Leu-Leu-Thr-Glu-Val-Glu-Thr-Pro-Ile-Arg-Asn-Glu-Trp -Gly-Aha-Lys(N ε -BrAc)-NH2 TFA salt (SEQ ID NO: 13), synthesized as a peptide bound to a protected resin on the APPLIEDBIOSYSTEMS 430A peptide synthesizer (APPLIED BIOSYSTEMS, CITY STATE). Starting with 0.5 mmoles of p-methylbenzylamine (MBHA) resin, this method uses a 4-fold excess (2 mmoles) of various N α -Boc protected amino acid. Side chain protection is Lys (Fmoc), Trp (formyl), Glu (OcHex), Arg (Tos), Thr (Bzl). The coupling is achieved by the activation of DCC and HOBT in methyl-2-pyrrolidone (NMP). Couple with acetic acid and introduce N-terminal acetyl group. Use 1:1TF...

Embodiment 2

[0191] Preparation of thiolated outer membrane protein complex (OMPC) of Neisseria meningitidis

[0192] The OMPC is obtained using techniques known in the art and described in US Patent No. 5,494,808. Using the general method described by Marburg et al. 1986, the thiolation with N-acetyl homocysteine ​​lactone was prepared by using aseptic technique. For NT-BrAcM2-15 and CT-BrAcM2-15, the thiolated OMPC was finally resuspended in N 2 Saturated 25mM borate, 0.15M NaCl, 2mM EDTA, pH 8.5; for reaction with NT-MalM2-15 and CT-MalM2-15, resuspend in 20mM HEPES, 0.15M NaCl, 2mM EDTA, pH 7.3. By appropriately diluting the thiolated OMPC to N 2 The thiol content was measured in saturated 0.1M sodium phosphate, 0.1M NaCl, 2mM EDTA, pH 7 buffer. Use N 2 A 50 mM DTNB stock solution saturated with 0.1 M sodium phosphate, 0.1 M NaCl, 2 mM EDTA, pH 7 buffer will add DTNB to a final concentration of 5 mM. After incubating for 15 minutes at room temperature, after subtracting the appropriate DT...

Embodiment 3

[0197] Preparation of maleimidized or alkyl halide-activated OMPC

[0198] All operations are performed aseptically. By adding a suitable volume of sterile 0.5M NaHCO 3 At NaHCO 3 Prepare a 50mM sterile OMPC aqueous solution (5.5mg / mL) at pH 8.5±0.1. Add 4-(N-maleimidomethyl)cyclohexane-1-carboxylic acid sulfosuccinimide ester (sSMCC) or (4-iodoacetyl)amino group dropwise to the buffered OMPC with gentle stirring Sulfosuccinimide benzoate (sSIAB) (10mM ice-cold H 2 Stock solution in O; chemicals purchased from PIERCE CHEMICAL CO., ROCKFORD, IL), giving a final concentration of 2.5 mM sSIAB or sSMCC and an OMPC concentration of approximately 3.8 mg / mL. N-hydroxysulfosuccinimide bromoacetate can also be used. The reaction was aged for 1 hour at 4°C and protected from light. After 1 hour, the reaction mixture was adjusted to pH 7.3 with sterile 1M sodium phosphate, and 300K molecular weight cut-off (MWCO) DISPODIALYZER (SPECTRUM INDUSTRIES, INC., RANCODOMINGUEZ, CA) with sterile 6.3...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Wavelengthaaaaaaaaaa
Login to View More

Abstract

The invention provides a vaccine against diseases caused by influenza virus infection and an immunization method. The vaccine contains peptides derived from the M2 and / or HA proteins of influenza virus coupled to carrier proteins.

Description

[0001] Cross reference of related applications [0002] This application claims the benefits of U.S. Provisional Application Nos. 60 / 452749 and 60 / 530690 filed on March 7, 2003 and December 18, 2003, respectively, which are incorporated herein by reference. Invention field [0003] The invention relates to the field of vaccines, vaccination and treatment for preventing and treating influenza virus diseases. Background of the invention [0004] Influenza viruses, enveloped, segmented negative-strand RNA viruses exist in two main types, influenza A and influenza B. The virus is an infectious substance that causes human influenza. According to the antigenic differences of the two viral transmembrane proteins hemagglutinin (HA) and neuraminidase (NA), influenza A viruses are further divided into subtypes. To date, three subtypes of influenza A have been identified in humans, H1N1, H2N2, and H3N2 (Hilleman, Vaccine 20, 3068-3087, 2002). The influenza B virus circulating almost exclusiv...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K39/12A61K39/29C12P21/06C12P19/34
Inventor V·M·加斯基R·约内斯库X·梁C·T·普日西基L·施J·W·希弗E·比安基P·因加利内拉A·佩西
Owner MERCK & CO INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com